Myeloid/lymphoid neoplasms with eosinophilia: clinical picture and therapeutic approaches
Abstract
Myeloid/lymphoid neoplasms with eosinophilia (M/Leo) and tyrosine kinase (TK) fusion genes constitute a separate category within the 2016 World Health Organization (WHO) classification. All these are characterized by blood or tissue eosinophilia and the presence of a unique genetic abnormality. M/Leo may have diverse clinical manifestations with variable response to TK inhibitors (TKI). PDGFRA-rearranged neoplasms (usually with detectable FIP1L1-PDGFRA) are found to be extremely sensitive to low dose of imatinib (IM at 100 mg daily) with nearly 100% hematological complete response rate. Moreover, >90% of IM treated patients may achieve long-term molecular response. IM discontinuation may result in sustained remission in c.50–60% of patients. An excellent response to IM (but at 400 mg/day) was also demonstrated for patients with PDGFRB rearrangements, but trials on IM cessation were not attempted. The FGFR1-rearranged neoplasms are associated with an aggressive disease course and allogeneic stem cell transplantation (allo-SCT) is the only potentially curative approach. Participation in clinical trials should be recommended. Recently, pemigatinib was found to be effective in a proportion of FGFR1-rearranged individuals. An aggressive outcome with rapid blast transformation is also characteristic for the JAK2-rearranged neoplasms. These patients should be included in clinical trials or attempted with ruxolitinib or fedratinib as a ‘bridge’ to allo-SCT. A new category of neoplasms with eosinophilia and FLT3 and ABL1 rearrangements has not yet been incorporated into the WHO 2016 classification. The prognosis is poor with a tendency to evolve into resistant acute leukemia. The treatment includes TKI with known activity against FLT3/ABL1 followed by allo-SCT.
Keywords: myeloidlymphoidneoplasmseosinophiliaPDGFRAPDGFRBFGFR1JAK2FLT3ABL1imatinibtreatment
References
- Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3): 607–612.e9.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–2405.
- Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017; 129(6): 704–714.
- Gerds AT, Gotlib J, Bose P, et al. Myeloid/Lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18(9): 1248–1269.
- Helbig G, Moskwa A, Hus M, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript — results of Polish multicentre study. Hematol Oncol. 2010; 28(2): 93–97.
- Srinivasan A, Scordino T, Baker A. Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRA rearrangement treated with imatinib mesylate: a pediatric case with long-term follow-up. J Pediatr Hematol Oncol. 2019; 41(4): 334–335.
- Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; 22(11): 1999–2010.
- Legrand F, Renneville A, MacIntyre E, et al. French Eosinophil Network. The spectrum of fip1l1-pdgfra-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013; 92(5): e1–e9.
- Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007; 120(3): 680–687.
- Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019; 94(10): 1149–1167.
- Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13): 1201–1214.
- Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007; 109(11): 4635–4640.
- Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009; 124(6): 1319–1325.e3.
- Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007; 21(6): 1183–1188.
- Metzgeroth G, Schwaab J, Naumann N, et al. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020; 4(3): 440–443.
- Rohmer J, Couteau-Chardon A, Trichereau J, et al. CEREO and GBMHM collaborators. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. Am J Hematol. 2020; 95(11): 1314–1323.
- Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017; 96(9): 1463–1470.
- Wang SC, Yang WY. Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports. World J Clin Cases. 2021; 9(1): 204–210.
- Bain B, Horny HP, Arber DA. Myeloid/lymphoid neoplasms and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: Swerdlow SH, Campo E, Harris NL. ed. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon 2017: 72–79.
- Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014; 123(23): 3574–3577.
- Bidet A, Chollet C, Gardembas M, et al. Molecular monitoring of patients with ETV6-PDGFRB rearrangement: implications for therapeutic adaptation. Br J Haematol. 2017; 182: 125–155.
- Zhang Y, Gao Y, Zhang H, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018; 131(20): 2256–2261.
- Kasbekar M, Nardi V, Dal Cin P, et al. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020; 4(13): 3136–3140.
- Goradia A, Bayerl M, Cornfield D. The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. Int J Clin Exp Pathol. 2008; 1(5): 448–456.
- Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014; 166(6): 809–817.
- Patterer V, Schnittger S, Kern W, et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol. 2013; 92(6): 759–769.
- Rumi E, Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015; 94(11): 1927–1928.
- Walz C, Erben P, Ritter M, et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood. 2011; 118(8): 2239–2242.
- Shao H, Wang W, Song J, et al. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leuk Res. 2020; 99: 106460.
- Zaliova M, Moorman AV, Cazzaniga G, et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016; 101(9): 1082–1093.
- Helbig G, Klion AD. Hypereosinophilic syndromes — an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Rev. 2021 [Epub ahead of print]: 100809.
